AU2021227095B2 - Daptomycin formulation - Google Patents
Daptomycin formulation Download PDFInfo
- Publication number
- AU2021227095B2 AU2021227095B2 AU2021227095A AU2021227095A AU2021227095B2 AU 2021227095 B2 AU2021227095 B2 AU 2021227095B2 AU 2021227095 A AU2021227095 A AU 2021227095A AU 2021227095 A AU2021227095 A AU 2021227095A AU 2021227095 B2 AU2021227095 B2 AU 2021227095B2
- Authority
- AU
- Australia
- Prior art keywords
- daptomycin
- formulation
- reconstitution time
- solid
- solid formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982945P | 2020-02-28 | 2020-02-28 | |
| US62/982,945 | 2020-02-28 | ||
| PCT/EP2021/054841 WO2021170807A1 (en) | 2020-02-28 | 2021-02-26 | Daptomycin formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021227095A1 AU2021227095A1 (en) | 2022-08-25 |
| AU2021227095B2 true AU2021227095B2 (en) | 2024-02-22 |
Family
ID=74797935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021227095A Active AU2021227095B2 (en) | 2020-02-28 | 2021-02-26 | Daptomycin formulation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230068866A1 (enExample) |
| EP (1) | EP4110303A1 (enExample) |
| JP (2) | JP2023516957A (enExample) |
| CN (2) | CN118873500A (enExample) |
| AU (1) | AU2021227095B2 (enExample) |
| BR (1) | BR112022015571A2 (enExample) |
| CA (1) | CA3168727A1 (enExample) |
| MX (1) | MX2022010378A (enExample) |
| WO (1) | WO2021170807A1 (enExample) |
| ZA (1) | ZA202208343B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2770366C2 (ru) | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019043008A1 (en) * | 2017-08-31 | 2019-03-07 | Xellia Pharmaceuticals Aps | DAPTOMYCIN FORMULATIONS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003055256A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第xiii因子製剤 |
| RU2607526C2 (ru) | 2009-11-23 | 2017-01-10 | Кьюбист Фармасьютикалз ЭлЭлСи | Липопептидные композиции и родственные способы |
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
-
2021
- 2021-02-26 EP EP21708627.1A patent/EP4110303A1/en active Pending
- 2021-02-26 BR BR112022015571A patent/BR112022015571A2/pt unknown
- 2021-02-26 AU AU2021227095A patent/AU2021227095B2/en active Active
- 2021-02-26 US US17/794,734 patent/US20230068866A1/en active Pending
- 2021-02-26 CA CA3168727A patent/CA3168727A1/en active Pending
- 2021-02-26 CN CN202410944805.5A patent/CN118873500A/zh active Pending
- 2021-02-26 CN CN202180011662.7A patent/CN115038431B/zh active Active
- 2021-02-26 JP JP2022551653A patent/JP2023516957A/ja active Pending
- 2021-02-26 WO PCT/EP2021/054841 patent/WO2021170807A1/en not_active Ceased
- 2021-02-26 MX MX2022010378A patent/MX2022010378A/es unknown
-
2022
- 2022-07-26 ZA ZA2022/08343A patent/ZA202208343B/en unknown
-
2025
- 2025-07-18 JP JP2025120933A patent/JP2025142200A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019043008A1 (en) * | 2017-08-31 | 2019-03-07 | Xellia Pharmaceuticals Aps | DAPTOMYCIN FORMULATIONS |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118873500A (zh) | 2024-11-01 |
| US20230068866A1 (en) | 2023-03-02 |
| ZA202208343B (en) | 2024-11-27 |
| CA3168727A1 (en) | 2021-09-02 |
| BR112022015571A2 (pt) | 2022-09-27 |
| MX2022010378A (es) | 2022-09-21 |
| AU2021227095A1 (en) | 2022-08-25 |
| JP2025142200A (ja) | 2025-09-30 |
| JP2023516957A (ja) | 2023-04-21 |
| CN115038431B (zh) | 2024-08-09 |
| CN115038431A (zh) | 2022-09-09 |
| WO2021170807A1 (en) | 2021-09-02 |
| EP4110303A1 (en) | 2023-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6239167B2 (ja) | リポペプチド組成物および関連する方法 | |
| US12053502B2 (en) | Daptomycin formulations | |
| KR20040085196A (ko) | 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법 | |
| JP2013511522A (ja) | ダプトマイシン製剤 | |
| CN113811290A (zh) | 达托霉素水性制剂 | |
| JP2025142200A (ja) | ダプトマイシン製剤 | |
| WO2017085696A1 (en) | Parenteral formulations of melphalan | |
| JP2025533237A (ja) | 液体ダルババンシン組成物 | |
| WO2023209731A1 (en) | Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation | |
| KR20230146515A (ko) | 개선된 동결건조 제형 | |
| WO2005123137A2 (en) | Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |